Internet Delivered Cognitive Rehabilitation for Mild Cognitive Impairments
Condition(s) studied
Investigational drug(s) / intervention(s)
eRehabCog: eRehabCog is a manualised internet delivered compensatory cognitive rehabilitation program (10 weeks, 1 hour per week, 10 hours in total). It is designed to improve patient self efficacy and participation in everyday life activities through compensatory strategy learning
CogMed QM: CogMed QM is an internet delivered training program (5 weeks, 2 hours per week, 10 hours in total) designed to improve patients working memory
Study summary
Acquired brain injury and neurological disorders cause cognitive deficits, which in turn cause reduced participation in everyday life. Cognitive rehabilitation, where patients learn about cognition, cognitive deficits and ways to circumvent problems arising from deficits can increase participation and quality of life. ERehabCog is an internet delivered cognitive rehabilitation program intended for patients suffering mild to moderate impairments. The program consists of information and homework assignments, which take approximately 10 weeks to complete with the assistance of a therapist. Effects are evaluated through measures of everyday life participation, mood, and life satisfaction and compared with an attention training program. This study aims to contribute to the evidence base for internet delivered cognitive rehabilitation for mild to moderate cognitive impairments. Evidence based interventions are vital to use the potential of technology to the benefit of affected patients.
Eligibility
Primary outcome measure(s)
- Mayo Portland Adaptability Inventory - fourth edition (MPAI-4), Participation subscale — Two weeks before intervention, at intervention start, at the end of treatment at 10 weeks, at six months post intervention ed
Change in T-score
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Danderyd Hospital | Stockholm | Stockholm County |
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06973018 on ClinicalTrials.gov ↗ ← All trials in Sweden